Glutathione S-transferase genotypes in systemic sclerosis and their association with clinical manifestations in early disease

Genes and Immunity

Volumn 2, Issue 4, 2001, Pages 236-238

  Tew, M B ^a   Reveille, J D ^a   Arnett, F C ^a   Friedman, A W ^a   McNearney, T ^b   Fischbach, M ^c   Ahn, C ^a   Tan, F K ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c 6431 Fannin MSB 5260 ^*

Author keywords

Glutathione S transferase; Oxidative damage; Scleroderma; Systemic sclerosis

Indexed keywords

SCLERODERMA;

GLUTATHIONE TRANSFERASE;

ARTICLE; ENZYMOLOGY; GENETICS; GENOTYPE; HUMAN; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; SJOGREN'S SYNDROME;

EID: 0035379873     PISSN: 14664879     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gene.6363756     Document Type: Article

References (13)

1. Rosen A, Casciola-Rosen L, Wigley F. Role of metal-catalyzed oxidation reactions in the early pathogenesis of scleroderma. Curr Opin Rheumatol 1997; 9: 538-543.
2. Bell DA, Taylor JA, Paulson DF et al. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993; 85: 1159-1164.
3. Heagherty AHM, Fitzgerald D, Smith A et al. Glutathione S-transferase GSTM1 phenotypes and protection against cutaneous malignancy. Lancet 1994; 343: 266-268.
4. Chen CL, Liu Q, Pui CH et al. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood 1997; 89: 1701-1707.
5. Morinobu A, Kanagawa S, Koshiba M et al. Association of the glutathione S-transferase M1 homozygous null genotype with susceptibility to Sjögren's syndrome in Japanese individuals. Arthritis Rheum 1999; 42: 2612-2615.
6. Ollier W, Davies E, Snowden N et al. Association of homozygosity for glutathione S-transferase GSTM1 null alleles with the RoVLa-autoantibody profile in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39: 1763-1764.
7. Mattey DL, Hassell AB, Dawes PT et al. Influence of polymorphism in the manganese superoxide dismutase locus on disease outcome in rheumatoid arthritis: evidence for interaction with glutathione S-transferase genes. Arthritis Rheum 2000; 43: 859-864.
8. Pemble S, Schroeder KR, Spencer SR et al. Human glutathione S-transferase Theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994; 300: 271-276.
9. Reveille JD, Fischbach M, McNearney T et al. Systemic sclerosis in three U.S. ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001; 30: (in press).
10. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-590.
11. Clements P, Lachenbruch P, Seibold JR et al. Inter- and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-1285.
12. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 2: 202-205.
13. Arnett FC, Reveille JD, Goldstein R et al. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma): an immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996; 39: 1151-1160.